Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)

FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer

IOVA : 26.00 (+0.19%)
Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

IOVA : 26.00 (+0.19%)
AZN : 40.58 (+0.62%)
CNCR : 21.14 (-0.58%)
MRK : 82.03 (+1.01%)
CHNA : 22.74 (+0.49%)
BMY : 43.05 (+0.65%)
NKTR : 32.09 (-0.77%)
Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

CELG : 89.82 (+0.39%)
IOVA : 26.00 (+0.19%)
AZN : 40.58 (+0.62%)
CNCR : 21.14 (-0.58%)
MRK : 82.03 (+1.01%)
CHNA : 22.74 (+0.49%)
LLY : 108.22 (+0.89%)
MRTX : 99.28 (-6.01%)
BMY : 43.05 (+0.65%)
NKTR : 32.09 (-0.77%)
Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it...

IOVA : 26.00 (+0.19%)
JLL : 142.97 (+2.11%)
Implied Volatility Surging for Iovance Biotherapeutics (IOVA) Stock Options

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

IOVA : 26.00 (+0.19%)
First Week of July 19th Options Trading For Iovance Biotherapeutics (IOVA)

Investors in Iovance Biotherapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA options...

IOVA : 26.00 (+0.19%)
Thinking about buying stock in Aurora Cannabis, Applied Materials, Iovance Biotherapeutics, NVIDIA, or Under Armour?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AMAT, IOVA, NVDA, and UAA.

AMAT : 51.03 (+0.59%)
NVDA : 175.66 (+2.53%)
ACBFF : 8.6900 (-12.80%)
IOVA : 26.00 (+0.19%)
UAA : 27.19 (+2.06%)
Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

- First patient dosed in pivotal Cohort 4 in study of lifileucel in advanced melanoma; regulatory submission planned for late 2020 -

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics to Participate in Upcoming Conferences in May

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Announces Clinical Programs Update

- Design of cervical cancer study amended in anticipation for regulatory interactions -

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

- Patient dosing commenced in pivotal metastatic melanoma cohort -

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel

- Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma -

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Announces April Scientific and Investor Presentations

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in March

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management...

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma -

IOVA : 26.00 (+0.19%)
Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food...

IOVA : 26.00 (+0.19%)

Van Meerten Stock Picks

Eldorado Gold
My Stock Pick of the Day belongs to the gold producer Eldorado Gold (EGO).
EGO -0.32
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar